Press Releases
Attorneys To Address Issues Affecting PTAB Proceedings for Biopharmaceutical and Medical Device Innovations
November 01, 2017

CHICAGO—Brinks Gilson & Lione intellectual property lawyers David Bernard, Joshua James, and Andrew McElligott will present "Selected Issues Impacting Biopharma and Medical Device Patent Post-Grant Review Proceedings,” in a webinar at noon CST on Thursday, November 9, 2017. Brinks shareholder and patent attorney Jason W. Schigelone will moderate. 

Bernard, James, and McElligott are patent attorneys in Brinks' post-grant patent and medical device practice groups. They will examine how joinder may delay issuance of final written decisions and offer strategies for avoiding such delays. They will also discuss the recent decision from the US Court of Appeals for the Federal Circuit in In re Aqua Products and its impact on amendment practice in post-grant proceedings, as well as Article III standing requirements for appealing Patent Trial and Appeal Board (PTAB) decisions to the Federal Circuit.

David Bernard focuses his practice on patent litigation and prosecution in diverse fields, including medical devices, industrial services, and telecommunications. His experience at both the federal district and appellate court levels includes fact and expert discovery, motion practice, and claim construction. Bernard also drafts opinions on complex non-infringement, right-to-use, and patentability issues.

Joshua James focuses his practice on patent litigation, particularly Hatch-Waxman pharmaceutical litigation in the federal courts and inter partes review (IPR) proceedings before the PTAB. His experience includes drafting appellate, IPR, and re-examination briefs; and drafting pleadings on invalidity, non-infringement, and claim construction issues.

Andrew McElligott focuses his practice on patent and trademark litigation. He represents leading companies in the pharmaceutical and medical device sectors, as well as consumer products manufacturers.

Moderator Jason Schigelone focuses his practice on protecting and defending a variety of technologies, particularly chemical, medical, and mechanical innovations. He represents clients through all stages of litigation in the district courts and before the Federal Circuit, and is experienced in both domestic and international patent prosecution matters.

For more information about the webinar, email

Brinks Gilson & Lione

Celebrating its centennial year in 2017, Brinks Gilson & Lione is one of the largest intellectual property law firms in the US, and helps clients around the world to protect and enforce their intellectual property rights. Brinks Gilson & Lione’s more than 140 lawyers, patent agents and scientific advisors assist clients in all aspects of patent, trademark, unfair competition, trade secret, and copyright law. Brinks attorneys provide informed counsel with respect to innovations in a range of complex and valuable technologies, including pharmaceuticals, chemicals, bioengineering, industrial manufacturing, electronics and software, and medical devices. More information is at